Form 4: Ernexa Therapeutics Senior VP of Finance Converts Restricted Stock Units

Sandra M. Gurrola, Senior VP of Finance at Ernexa Therapeutics Inc., converted 30 restricted stock units into common stock on June 21, 2025, increasing her direct beneficial ownership of common stock to 110 shares.

Summary

• Sandra M. Gurrola, Senior VP of Finance at Ernexa Therapeutics Inc. (ERNA), reported a change in beneficial ownership.
• On June 21, 2025, Gurrola acquired 30 shares of Ernexa Therapeutics common stock.
• This acquisition resulted from the conversion of 30 restricted stock units (RSUs).
• Following this transaction, Gurrola directly beneficially owns 110 shares of common stock.
• The RSUs converted were part of a grant of 118 restricted stock units made on June 21, 2021, which vest in four substantially equal installments.

Sentiment

Score: 6

Explanation: The document reports a routine vesting and conversion of restricted stock units by a senior executive, which is an expected part of compensation. It slightly increases direct insider ownership, which can be viewed as a minor positive alignment of interests.

Positives

• Conversion of restricted stock units into common stock indicates a vesting event, which is a standard part of executive compensation.
• The increase in direct common stock ownership by a Senior VP of Finance aligns her interests with shareholders.

Negatives

• No explicit negatives are present in this routine insider transaction report.

Risks

• No specific risks are detailed in this Form 4 filing.

Future Outlook

NA

Industry Context

This is a routine insider transaction common across all industries for publicly traded companies, reflecting executive compensation structures.

Comparison to Industry Standards

• The vesting and conversion of restricted stock units are standard practices in executive compensation across various industries, including biotechnology/pharmaceuticals (implied by 'Therapeutics'). The specific number of shares (30) is small, but the mechanism is typical. No specific comparable companies or projects are mentioned in the document.

Stakeholder Impact

• Shareholders: The transaction slightly increases the direct ownership stake of a senior executive, potentially aligning management interests more closely with shareholders.
• Employees: No direct impact on general employees is indicated.

Next Steps

• Future vesting events for the remaining restricted stock units from the June 21, 2021 grant are expected as per the original vesting schedule.

Key Dates

Keywords

Ernexa Therapeutics, ERNA, Form 4, Insider transaction, Beneficial ownership, Restricted Stock Units, RSU conversion, Sandra Gurrola, Executive compensation